共 42 条
- [1] DIFFERENCES IN UTILIZATION OF THIRD LINE THERAPY FOR OVERACTIVE BLADDER AMONG FPMRS AND NON- FPMRS TRAINED UROLOGISTSNEUROUROLOGY AND URODYNAMICS, 2023, 42 : S213 - S214Huang, AaronHarandi, ArshiaRamgopal, JenniferAronov, JonathanFonseca, PhilipSmith, HollyShkolnik, BrianMiller, ConnellyKim, Jason
- [2] TRENDS IN THIRD LINE THERAPY UTILIZATION FOR OVERACTIVE BLADDER AMONGST GENERAL UROLOGISTS, ADVANCED PRACTICE PROVIDERS, AND FPMRS SUBSPECIALISTSNEUROUROLOGY AND URODYNAMICS, 2018, 37 : S584 - S584Lloyd, JessicaGuzman, JuanGiusto, LauraZahner, PatriciaMoore, CourtenayGoldman, HowardRackley, RaymondVasavada, Sandip
- [3] First-line treatment for non-neurogenic overactive bladderPROGRES EN UROLOGIE, 2020, 30 (14): : 904 - 919Game, X.Phe, V
- [4] Trends in utilization of non-first-line topical acne medications among children, adolescents, and adults in the United States, 2012-2016PEDIATRIC DERMATOLOGY, 2021, 38 (05) : 1066 - 1073Afarideh, MohsenBaisi, Katinna E. RodriguezDavis, Dawn M. R.Hand, Jennifer L.Tollefson, Megha M.
- [5] Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinomaHEPATOBILIARY SURGERY AND NUTRITION, 2020, 9 (04) : 414 - 424Lin, JianzhenYang, XuLong, JunyuZhao, SonghuiMao, JinzhuWang, DongxuBai, YiBian, JinZhang, LeiYang, XiaoboWang, AnqiangXie, FucunShi, WeiweiYang, HuayuPan, JieHu, KeGuan, MeiZhao, LinHuo, LiMao, YileiSang, XintingWang, KaiZhao, Haitao
- [6] Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancerCANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (12)Tan, YangLiu, KaiZhu, ChengpeiWang, ShanshanWang, YunchaoXue, JingnanNing, CongZhang, NanChao, JiashuoZhang, LonghaoLong, JunyuYang, XiaoboZeng, DaobingZhao, LijinZhao, Haitao
- [8] Correction: Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancerCancer Immunology, Immunotherapy, 74 (6)Yang TanKai LiuChengpei ZhuShanshan WangYunchao WangJingnan XueCong NingNan ZhangJiashuo ChaoLonghao ZhangJunyu LongXiaobo YangDaobing ZengLijin ZhaoHaitao Zhao
- [9] GEMCYTABIN (CYTOGEMr (R)) AND CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED BLADDER CANCER: RESULTS OF A PROSPECTIVE OPEN-LABELED NON-COMPARATIVE NON-RANDOMIZED STUDYONKOUROLOGIYA, 2009, 5 (04): : 46 - 49Matveev, V. B.Volkova, M. I.Konstantinova, M. M.Schapligin, L. V.Manikhas, G. M.